Altimmune, Inc. (NASDAQ:ALT – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages […]
GAITHERSBURG, Md., May 31, 2023 Altimmune, Inc. , a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be. | May 31, 2023
Sectoral Asset Management Inc. grew its holdings in Altimmune, Inc. (NASDAQ:ALT – Get Rating) by 27.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 342,500 shares of the company’s stock after acquiring an additional 73,400 shares during the period. Sectoral Asset Management […]